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Background: Despite bronchoscopic lung volume reduction (BLVR) with valves is a minimally invasive 
treatment for emphysema, it can associate with some complications. We aimed at evaluating the rate and 
type of complications related to valve treatment and their impact on clinical outcomes.  
Methods: It is a retrospective multicenter study including all consecutive patients with severe 
heterogeneous emphysema undergoing BLVR with endobronchial valve treatment and developed any 
complications related to this procedure. The type of complication, the time of onset, the treatment required 
and the out-come were evaluated. Response to treatment was assessed according to the minimal clinically 
important difference (MCID) as follows: an improvement of ≥15% in forced expiratory volume in one 
second (FEV1); of −8% in residual volume (RV); of ≥26 m in 6-minnute walking distance (6MWD); and  
of ≥4 points on the St. George’s Respiratory Questionnaire (SGRQ). Target lobe volume reduction  
(TLVR) ≥350 mL was considered significant.
Results: One hundred and seven out of 423 (25.3%) treated patients had complications related to valve 
treatment including pneumothorax (17.3%); pneumonia (1.7%), chronic obstructive pulmonary disease (COPD) 
exacerbation (0.9%), respiratory failure (1.4%), valve migration (2.1%), and hemoptysis (1.9%). In all cases 
complications resolved with appropriate treatment including removal of valves in 21/107 cases (19.6%). Patients 
with TLVR ≥350 mL (n=64) vs. those <350 mL (n=43) had a statistically significant higher improvement in 
FEV1 (19.0%±3.9% vs. 3.0%±0.9%; P=0.0003); in RV (−10.0%±4.8% vs. −4.0%±2.9%; P=0.002); in 6MWD 
(33.0±19.0 vs. 12.0±6.3 metres; P=0.001); and in SGRQ (−15.0±2.9 vs. −8.0±3.5 points; P=0.01). Only patients 
with TLVR ≥350 mL met or exceeded the MCID cut-off criteria for FEV1 (19.0%±3.9%), RV (−10.0%±4.8%), 
6MWT (33.0±19.0 metres), and SGQR (−15.0±2.9 points). Five patients (1.2%) died during follow-up for 
causes not related to valves treatment neither to any of the complications described.
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Introduction
Emphysema is a leading cause of morbidity and mortality. 
Lung transplantation is the only curative treatment but 
the strict eligibility criteria and an inadequate supply of 
donor organs make it available only in a limited number of 
patients. Lung volume reduction surgery (LVRS) has been 
proposed as a viable option for patients with heterogeneous 
emphysema. Despite the positive clinical results, LVRS is 
associated with significant morbidity (20–30%) and high 
90 days operative mortality (7.9%) (1). Thus, over the 
years alternative minimally invasive techniques have been 
explored as the implantation of non-blocking (i.e., coil, 
sealant, vapor) or blocking devices [endobronchial valves 
(EBV)] to obtain bronchoscopic lung volume reduction 
(BLVR). Among these, EBV are the best studied to date. 
EBVs are designed to achieve BLVR by inducing lobar 
atelectasis. Exclusion of the most destroyed emphysematous 
lobe with EBV allows air to exit during expiration, but 
stops it from entering during inspiration, thus resulting in 
atelectasis of the target lobe and reducing hyperinflation. 
Heterogeneous emphysema and the absence of interlobar 
collateral ventilation (CV-negative patients) are the main 
predictive factors for the success of the procedure. EBV 
treatment is a well-tolerated procedure that provides 
clinically significant results in selected cases, but it can be 
associated with different complications that are challenge 
to treat due to poor clinical conditions of patients (2-8). 
Most of the papers published focused on the clinical results 
of EBV treatment while the incidence and management 
of complications related to EBV treatment remain less 
explored issue. The aim of the present paper is to evaluate 
the rate and type of complications related to EBV treatment 
and their impact on clinical outcomes. 
Methods
Study design
This is a retrospective multicenter study including 
8Italian centers with long experience in EBV treatment. 
All consecutive patients with heterogeneous emphysema 
undergoing BLVR with Zephyr EBVs from January 2012 to 
May 2017 and developing any type of complication related 
to the procedure were considered. Patients with lack of data 
regarding the type of complications and their treatment, 
and/or with incomplete follow-up were excluded. The 
goals of the paper were (I) to evaluate the incidence and 
the management of complications related to the procedure 
and (II) whether these complications could affect clinical 
outcome. Being it a retrospective study, the management 
of complications and the timing of follow-up were not 
standardized but decided by each participating center 
according to personal experience and guidelines. The study 
design was approved by the Ethic Local Committee of the 
two Coordinating Centers (University of Campania “Luigi 
Vanvitelli” and Sapienza University-Rome Sant’ Andrea 
Hospital). Patients signed a written informed consent for 
the EBV treatment and they were aware that their data 
could be anonymously analyzed for scientific purposes only. 
As the data in this current analysis were retrospectively 
analyzed, no further patients consent was required.  
Study population
Patients were scheduled for EBV treatment according to 
the published best practice criteria (9-17). All patients had 
a diagnosis of severe emphysema (GOLD stage III or IV) 
and a residual volume (RV) ≥150% predicted. Emphysema 
Conclusions: Valve treatment is a safe and reversible procedure. The presence of complications 
seems not to have a significant impact on clinical outcome in patients with lobar atelectasis. Due to poor 
clinical conditions and possible complications, BLVR should be performed in high volume centers with a 
multidisciplinary approach. 
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distribution was assessed by high resolution computed 
tomography (HRCT) scan with volume rendering and lung 
perfusion scan; only lobes showing a clear density reduction 
without perfusion were treated (9,10). According to 
standard clinical practice (11-13), only patients considered 
as CV-negative for completeness of fissure ≥90% on 
HRCT-analysis and/or for the absence of CV at Chartis 
assessment were treated. Pulmonary function tests (PFTs) 
included forced expiratory volume in one second (FEV1), 
forced vital capacity (FVC), total lung capacity (TLC), RV, 
diffusing capacity (DLCO), 6-minute walking test (6MWT), 
PaO2 and PaCO2 (measured at rest while breathing room 
air). All pulmonary function data were presented as a 
percentage of predicted values for the patient’s age, gender 
and height. Quality of life was measured by the St. George’s 
Respiratory Questionnaire (SGRQ), ranging from 0 to 100, 
with a higher score indicating a worse quality of life. After 
treatment, all patients underwent standard clinical and 
radiological follow-up performed 3, 6, 12 months after the 
valves implantation, and then yearly. 
Procedure of valve implant
The type of anesthesia used during the procedure varied across 
the centers, depending on patient condition and physician 
preference. Generally, the procedure was performed with IV 
sedation, spontaneous breathing, and flexible bronchoscopy. 
Alternatively, general anesthesia with either a laryngeal mask 
or endotracheal tube or rigid bronchoscopic to provide positive 
airway pressure or intermittent negative pressure ventilation 
was used. Three different size of valves were used: EBV 4.0 
or EBV 4.0 LP (shorter), and EBV 5.5 for bronchial lumens 
with diameters of 4.0–7.0 mm and of 5.5–8.5 mm, respectively. 
After estimating the size of the target bronchus with a 
dedicated catheter, the valves were delivered through the same 
catheter to obtain the complete occlusion of the target lobe. 
All patients were hospitalized for a minimum of 48–72 hours 
after the procedure. A chest X-ray was performed few hours 
later or the day after the procedure according to the center’s 
experience, to assess the lobar volume reduction and to 
determine EBV location and to evaluate the presence of 
pneumothorax or other complications. In presence of any 
complications, additional diagnostic exams and treatment were 
carried out. 
Morbidity and mortality 
The type of complications, the time of onset from EBV 
implant (hour or days), the treatment and clinical and 
functional out-come were analyzed. In agreement with 
previous studies, the clinical response to treatment was 
assessed using the principle of minimal clinically important 
differences (MCID) that was defined according to the 
following specific responders criteria: an improvement 
of ≥15% in FEV1; an improvement of −8% in RV; an 
improvement of ≥26 m in 6MWT; an improvement of 
≥4 points on the SGRQ. A target lobe volume reduction 
(TLVR) ≥350 mL defined the significant cut-off criterion 
for lung volume reduction. 
Statistical analysis
Data were expressed as means ± standard deviation (SD) for 
continuous variables and absolute number and percentage 
for categorical variables. The delta for each variable was 
calculated by the variation between the value of the last 
follow-up and the baseline value. The difference between 
the different groups were calculated using Student’s t-test 
for quantitative variables and Chi-square test for categorical 
variable. A P value <0.05 was considered statistical 
significant. MedCalc statistical software (version 12.3, 
Broekstraat 52; 9030 Mariakerke; Belgium) was used for the 
analysis. 
Results
In the study period 423 patients underwent EBV 
treatment for severe emphysema. Of these, 107 (25.3%) 
patients developed EBV-related complications and 
were included in the study. The characteristics of the 
study population are summarized in Table 1. Mean age 
was 63.2±11.0 years old and most of patients were male 
(77.6%). Thirty-five patients (32.7%) presented pre-
procedural co-morbidities. Before treatment, the mean 
value of FEV1% and of RV% were 43.0±4.9 and 237±19, 
respectively. The left upper lobe (LUL) was the most 
treated lobe (43.9%). The mean number of valves per 
patient were 2.9±0.7 and most of the procedures were 
performed with conscious sedation (63.6%). 
Complications related to valves 
The type of complications, treatment and outcome are 
summarized in Table 2. During the study period 5 out of 
423 (1.2%) treated patients died 27.0±3.9 months from 
treatment. In all cases the cause of death was not related 
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to valves treatment. Two patients died for lung and brain 
cancer, respectively, one for stroke, one for myocardial 
ischemic attack, and one for drug-induced anaphylaxis. 
Pneumothorax
Pneumothorax was the most common complication, 
observed in 73 out of 423 (17.3%) treated patients. Among 
these, 54/73 (74.0%) patients had a TLVR >350 mL. In 
86.3% (63/73 patients) of cases pneumothorax occurred 
during hospitalization (22.0±9.3 hours after valve implant) 
and in 13.7% (10/73 patients) pneumothorax occurred after 
a mean time of 5.3±2.8 months. The treatment included 
clinical observation in 23 (31.5%) cases (Figure 1); chest 
drainage in 38 (52.1%) cases for the presence of massive 
pneumothorax (Figure 2), and chest drainage with valve(s) 
removal in 12 (16.5%) cases for persistent air leaks (more 
than 5 days) (Figure 3). In all cases the pneumothorax 
successfully resolved after a mean time of 4.0±1.9 days. 
Eight of 12 (66.7%) patients, in whom the valves were 
removed, underwent re-implantation of the valves and 
TLVR >350 mL was obtained in seven of these (87%). 
Respiratory failure
Respiratory failure was observed in 6 (1.4%) patients. Of 
these four patients presented a TLVR >350 mL. In 4 (66.7%) 
cases, respiratory failure developed during hospitalization 
(mean time 9.3±5.4 hours) and in the remaining 2 (33.3%) 
cases 4.2±1.7 months later. The treatment required invasive 
ventilation more than 24 hours in 3 (50.0%) cases, medical 
therapy in 2 (33.3%) cases and medical therapy with valve 
removal in 1 (16.7%) case. In all cases, respiratory failure 
resolved.  
Pneumonia
Pneumonia was observed in 7 (1.7%) patients 7.5±2.3 months 
after the treatment. Six (85.7%) patients presented a TLVR 
>350 mL. Pneumonia resolved with medical therapy in 5 (71.4%) 
cases. In 2 (28.6%) patients the valves were removed and in only 
one they were re-implanted obtaining a TLVR >350 mL. 
COPD exacerbation
COPD exacerbation was observed in 4 (0.9%) patients. 
Only one patient presented a TLVR >350 mL. In one case 
COPD exacerbation occurred during hospitalization and 
its treatment required the removal of the valve. In the other 
three cases it occurred 2.9±0.7 months after treatment and 
resolved with medical therapy alone. 
Migration and/or expectoration
Migration and/or expectoration were observed in 9 (2.1%) of 
patients (Figure 4). In 3 (33.3%) patients it occurred during 
hospitalization (mean time: 32±11 hours from implant) 
Table 1 Characteristics of study population (n=107)
Variable Value
Age, mean ± SD (years) 63.2±11.0
Sex (male/female), n (%) 83 (77.6)/24 (22.4)
Pre-procedural comorbidities, n (%) 35 (32.7)
Cardio-vascular 15 (14.0)
Cerebral 5 (4.7)
Diabetes 7 (6.5)
Gastric 3 (2.8)
Infective 2 (1.9)
Cancer 3 (2.8)
O2 saturation (%), mean ± SD 93.0±3.5
pO2 (%), mean ± SD 75.0±9.2
pCO2 (%), mean ± SD 39.0±5.5
FEV1%, mean ± SD 43.0±4.9
FVC%, mean ± SD 37.0±3.7
RV%, mean ± SD 237±19
TLC%, mean ± SD 135±23
6MWT, mean ± SD (metres) 199±31
DLCO%, mean ± SD 57.0±8.9
SGRQ, mean ± SD (points) 60.0±3.1
Target lobe, n (%)
RUL 31 (29.0)
RLL 19 (17.8)
LUL 47 (43.9)
LLL 10 (9.3)
Valve per patient, mean ± SD 2.9±0.7
Type of procedure, n (%)
Conscious sedation 68 (63.6)
General anaesthesia 39 (36.4)
SGRQ, St. George’s Respiratory Questionnaire; FEV1, forced 
expiratory volume in one second; FVC, forced vital capacity; 
RV, residual volume; TLC, total lung capacity; 6MWT, 6-minute 
walking test; DLCO, diffusing capacity of the lung for carbon 
monoxide; RUL, right upper lobe; RLL, right lower lobe; LUL, left 
upper lobe; LLL, left lower lobe.
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and in 6 (66.7%) of patients 3.7±2.1 months from implant. 
No patient had a significant TLVR. In all cases the valves 
were re-implanted after a mean time of 3.5±1.3 months 
obtaining a TLVR >350 mL in six patients. An example of 
valve migration is reported in Figure 4.
Hemoptysis
Hemoptysis was observed in 8 (1.9%) patients 10.0±6.9 months 
after valve implant. In one case hemoptysis was massive due 
the presence of a micetoma and required embolization. In five 
cases it was mild and due to granuloma formation (Figure 5). 
In all cases the valves were removed and in 2 of these the 
granulomas were resected with laser. In the remaining two 
patients, hemoptysis resolved with medical therapy. Only 
1 (20.0%) patient underwent re-implantation of valve 
obtaining a TLVR >350 mL. An example of hemoptysis due 
to granuloma is reported in Figure 5. 
Clinical outcome 
Data are summarized in Table 3. The rate of patients with 
TLVR >350 mL did not change after the treatment of 
complications (61.6% vs. 59.8%, P=0.9) confirming that 
whatever complication did not affect the lobar atelectasis rate. 
Patients with TLVR >350 mL (n=64) compared to those 
with TLVR <350 mL (n=43) had a significant improvement 
in delta FEV1 (19.0%±3.9% vs. 3.0%±0.9%; P=0.0003); 
in delta RV (−10.0%±4.8% vs. −4.0%±2.9%; P=0.002); in 
delta 6MWT (33.0±19.0 vs. 12.0±6.3 metres; P=0.001); 
and in delta SGRQ (−15.0±2.9 vs. −8.0±3.5 points; P=0.01). 
Only patients having TLVR ≥350 mL met or exceeded 
the MCID cut-off criteria for FEV1 (19.0%±3.9%), RV 
(−10.0%±4.8%), 6MWT (33.0±19.0 metres), and SGQR 
(−15±2.9 points) while in patients with TLVR <350 we 
observed only the MCID for SGQR (−8.0±3.5 points). 
Figure 1 Small, asymptomatic pneumothorax (white arrow) 
(A) spontaneously resolved with clinical observation (B). Lobar 
atelectasis (*) of left upper lobe was preserved after resolution of 
pneumothorax. 
Figure 2 Massive, symptomatic, pneumothorax (white arrow) (A) 
resolved with insertion of chest drainage (B). Lobar atelectasis (*) 
of left upper lobe was preserved after resolution of pneumothorax.  
A
B
A
B
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Discussion
EBV treatment in patients with heterogeneous emphysema 
and with proven absence of CV provided significant clinical 
benefits (2-8). The lobar atelectasis obtained with EBV 
implant mimics the same physiologic effects of LVRS 
in terms of reduction of RV and improves respiratory 
mechanics a larger application and shorter length of 
Figure 3 Massive, symptomatic pneumothorax following insertion 
of three valves in the left upper lobe (A). Pneumothorax resolved 
with chest drainage (B) but the persistent air-leaks required the 
removal of the 2th and the 3th valves (C). 
A
B
C
Figure 4 A large valve dislocated and obstructed the main left 
bronchus (A). It was extracted using rigid bronchoscopy (B) 
restoring the air way patency (C). It was well evident the formation 
of granulomas due to the injury of air-way mucosa by valve. LUB, 
left upper bronchus; LLB, left lower bronchus. 
A
B
C
Valve
Valve
Carina
LUB
LLB
Granuloma
Forceps
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hospital stay, and reduced morbidity and mortality. EBV 
treatment is per se a safe and well tolerated procedure. 
A recent metanalysis by Liu et al. (14) showed that EBV 
treatment in comparison with standard medication and 
sham EBV did not increase the overall rate of mortality 
and morbidity except for mild hemoptysis which was 
more common in the EBV groups than in control groups 
(P=0.03). However, EBV treatment as well as most thoracic 
procedures can be accompanied by severe and less severe 
complications as reported in randomized clinical trials 
(RCTs) (2-7). Despite all, this issue is not largely evaluated 
in the literature. All published papers (15-17) focused on the 
incidence, treatment and clinical outcome of pneumothorax 
which is the most frequent EBV complication but there 
are other potential complications related to EBV treatment 
that remain under evaluated. To overcome these limits, we 
conducted this retrospective multicenter study with the aim 
of evaluating all complications due to EBV treatment and 
their impact on clinical outcome, an issue which has not 
been reported before. 
As expected, pneumothorax was the most frequent 
complications (17.3% of patients). Early trials as the US 
VENT (2) and its European cohort (3) reported a lower 
rate of pneumothorax (4% and 8%, respectively) than 
the more recent (3,4,6) where it ranged between 17% 
and 23%. The reason for this different pneumothorax 
is the better selection of patient with only CV-negative 
being treated. In the VENT study (2) 67% of patients in 
the treatment group presented incomplete fissure at CT 
scan (CV-positive patients) while more recent trials as 
STELVIO (3), LIVE (4), and TRANSFORM (6) enrolled 
only patients defined as CV-negative (complete fissure 
at visual CT scan and/or CV-negative at Chartis). Since 
pneumothorax seems to be an indicator of successful 
valve therapy, there is the tendency among physicians to 
consider it as a “good complication” (if it is ethically right 
to consider a complication as “good”). In line with this 
evidence, in our series the incidence of pneumothorax was 
higher in responders (having a TLVR more than 350 mL) 
compared to non-responders. Despite all, 10/73 (13.7%) 
Figure 5 Hemoptysis due to the granuloma formation (A) resolved 
with valve removal (B).
A
B
Valve
Granuloma
Granulomas
Table 3 Clinical changes according to the minimal clinically important difference (MCID) cut-off criteria 
Variables MCID cut-off criteria TLVR ≥350 mL (n=64) TLVR <350 mL (n=43) P value
Delta FEV1% ≥15 19.0±3.9 3.0±0.9 0.0003
Delta RV% −8 −10.0±4.8 −4.0±2.9 0.002
Delta 6MWT (metres) ≥26 33.0±19.0 12.0±6.3 0.001
Delta SGQR (points) ≥4 −15.0±2.9 −8.0±3.5 0.01
TLVR, target lobe volume reduction; SGRQ, St. George’s Respiratory Questionnaire; FEV1, forced expiratory volume in one second; RV, 
residual volume; 6MWT, 6-minute walking test; RV, residual volume.
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patients without significant lobar collapse experienced 
pneumothorax. This phenomenon is also reported in the 
European cohort of the VENT study (3) and in the study of 
Gompelmann et al. (15) where 7/25 (28%) and 42/70 (60%) 
patients, respectively, developed pneumothorax despite no 
lobar collapse. In agreement with previous RCTs (3,4) and 
Gompelmann’s study (15), pneumothorax (86%) occurred 
within the first 72 hours confirming need to prolong 
hospitalization for a minimum of 72 hours. In 3 (4.1%) of 
our patients, pneumothorax occurred during the procedure. 
Thus, a sudden and an unexpected respiratory failure 
during or immediately after valve implantation should make 
you suspect a pneumothorax and physicians should be ready 
for an emergency treatment (i.e., chest drainage). In theory, 
the rapid re-expansion of the ipsilateral untreated lung 
due to sudden atelectasis favors the rupture of parenchyma 
with consequent pneumothorax. On the other hand, 10/73 
(13.7%) of our patients developed pneumothorax several 
months after treatment making difficult to define whether 
this event is due or not to the valve treatment.  
Due to the retrospective nature of the study, each 
participant centers managed pneumothorax according to 
their experience, but in all cases the treatment was in line 
with standard recommendations (16,17). A “watch and wait 
strategy” was applied in 31.5% of cases for asymptomatic 
pneumothorax. Chest tube drainage insertion was required 
in 68.5% of cases for symptomatic pneumothorax. 
This datum is in line with the STELVIO study (3) and 
Gompelmann’s study (15) where 80% of patients with 
pneumothorax underwent chest insertion. In 16.4% of cases, 
persistent air-leaks (more than 5 days) required removal 
of the valve. The STELVIO study (3) and Gompelman’s 
study (15) reported a rate of valve removal of 50% and 
44%, respectively, for the management of pneumothorax 
and persistent air-leaks. In all cases the persistent air leaks 
resolved with no need for surgery. 
Other complications seen in our series were pneumonia 
(1.7%), COPD exacerbation (0.9%), respiratory failure 
(1.4%), valve migration or expectoration (2.1%) and 
hemoptysis (1.9%) caused by micetoma or granulation. 
Their rates were similar to RCTs studies summarized in 
Table 4 and resolved with appropriate medical treatment 
and in selected cases with valve removal (nine cases). 
Only COPD exacerbation presented a lower rate in our 
than in other series. In theory, COPD exacerbation is a 
phenomenon that occur in all COPD patients. Thus, in 
our study it could be under evaluated due to the difficult 
to define whether it was related or not to valve treatment 
considering the retrospective nature of the study and the 
lack of a control group.   
Table 4 Review of the complications related to valve-treatment reported in the randomized control trials (RCTs) 
Variables
US VENT 
(n=214), n (%)
EU VENT 
(n=111), n (%)
STELVIO 
(n=34), n (%)
LIVE (n=343), 
n (%)
BeLieVeR-HIFi 
(n=25), n (%)
TRANSFORM 
(n=65), n (%)
Present study 
(n=423), n (%)
Death 6 (2.8) 6 (5.4) 1 (2.9) 0 2 (8.0) 1 (1.5) 5 (1.2)
Pneumothorax 9 (4.2) 9 (8.1) 6 (17.6) 35 (10.2) 2 (8.0) 15 (23.1) 73 (17.3)
COPD 
exacerbation
22 (10.3) 42 (37.8) 4 (11.8) 5 (1.5) 5 (20.0) 6 (9.2) 4 (0.9)
Pneumonia 17 (7.9) 20 (18.0) 3 (8.8) 4 (1.2) 2 (8.0) 6 (9.2) 7 (1.7)
Valve dislocation 10 (4.7) 10 (9.0) 2 (5.9) 3 (0.9) 5 (20.0) – 9 (2.1)
Granulation 9 (4.2) 5 (4.5) 1 (2.9) – – – 5 (1.2)
Respiratory 
failure
3 (1.4) 10 (9.0) – 1 (0.3) – 8 (12.3) 6 (1.4)
Hemoptysis 13 (6.1) 14 (12.6) – 1 (0.3) – 1 (1.5) 8 (1.9)
Cardiovascular 
disease
6 (2.8) 4 (3.6) – – – – –
Lobar torsion 1 (0.5) 1 (0.9) 2 (5.8) – – – –
Other – – 4 (11.8) 17 (5.0) – 13 (20.0) –
COPD, chronic obstructive pulmonary disease.
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EBV treatment is a reversible procedure and complete 
resolution of complications without further side effects 
was observed in all patients where the valves were removed 
(21 patients). However, we found that again the presence 
of lobar atelectasis after the resolution of the complication 
was the only predictive factor for significant clinical 
improvement. This is line with the VENT study and 
Gompelmann’s analysis. In the VENT study (2), patients 
who experienced pneumothorax had similar clinical 
benefits in terms of FEV1 and 6MWD compared to the 
subgroup of patients with complete fissure and without any 
complication. In Gompelmann’s series (15), 3 months after 
pneumothorax, valve therapy was associated with significant 
improvement in all lung function parameters except VC in 
patients with lobar atelectasis. Thus, patients, in whom the 
valves are removed for the management of complication, 
should be reviewed for re-implanting valves in order to 
obtain lobar collapse. Furthermore, we observed in 23/73 
(31.5%) patients with pneumothorax the reexpansion of 
the target lobe despite the valves were not removed. In 
theory, the abnormal movement of the lung during the 
pneumothorax could favor a small dislocation of the valves, 
resulting in a lack of significant TLVR. Thus, in these 
patients a CT scan followed by bronchoscopy check is 
indicated in order to diagnose any valve dislocation. 
Our study confirmed that delayed complications can 
occur also several months after valve implant, underlying 
the necessity of a prolonged follow-up. Because the patients 
will often back under the care of their primary physicians, it 
is mandatory to inform the patient and his family regarding 
the most common clinical signs of the complications. 
A sudden and unexpected chest pain associated with 
respiratory failure could be related to pneumothorax, a loss 
of clinical benefit or increased coughing could be associated 
with valve migration (18,19), hemoptysis with granuloma 
formation, while persistent infection with pneumonia. 
In this way, the patient and his/her family are able to 
understand when to alert their threatening physicians and/
or refer to a local hospital for an emergency treatment. 
EBV treatment is not largely performed and in the most 
hospital there is a lack of knowledge about the role, the 
function, and the complications of valves. Thus, establishing 
a link with minor hospitals should be encouraged in order 
to allow the early transfer of the patient to the threatening 
expert centers after stabilization of his/her clinical 
condition. BLVR has been developed for people considered 
to be too disabled to withstand LVRS, thus the treatment of 
any complication could be a challenge due to poor clinical 
condition of the patient. There are cases of death (20) 
reported in patients who had pneumothorax after discharge 
from the hospital. In the BeLieVeR-HIFi (6) study two 
patients died and one occurred as a complication of valve 
removal. Thus, BLVR should be performed in expert 
centers by a multi-disciplinary approach including thoracic 
surgeons, anesthesiologists and pulmonologists. 
The retrospective and multicentric nature of the study, 
the different experience among participating centers, 
and the non-standardized protocol for the treatment of 
complications are all factors that should be considered 
before drawing definitive conclusions from our results. 
Conclusions
Despite safe and well tolerated, EBV treatment could be 
associated with early and delayed complications. However, 
it is a reversible procedure and complete resolution of 
complications is obtained with or without valve removal. 
Complications did not have significant impact on clinical 
outcome in patients with lobar atelectasis. However, it is 
crucial to remember that some of these complications could 
be potentially life-threatening if not promptly treated. 
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